Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

INTRODUCTION: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Knappskog, Stian, Chrisanthar, Ranjan, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Leirvaag, Beryl, Miletic, Hrvoje, Lønning, Per E
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3446381/
https://ncbi.nlm.nih.gov/pubmed/22420423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados